Intelligence · Clinical Development
Pipeline search results
Programs matching “chemotherapy” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 127 pipeline programs matching "chemotherapy" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
IVEMEND for Delayed chemotherapy induced na…
AXIM BIOTECHNOLOGIES, INC.
Delayed chemotherapy induced nausea and vomiting (CINV)
1 trial -
Induction Chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
Investigator's choice of Chemotherapy
Zentalis Pharmaceuticals
Ovarian Cancer
1 trial -
MK-2870-020
Merck Sharp and Dohme
Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.
1 trial -
Mimetic granules of Yiqi-Wenjing prescriptions
The First People's Hospital of Lianyungang
Chemotherapy-induced Peripheral Neuropathy
1 trial -
NEPA-22-01
Helsinn Birex Pharmaceuticals Ltd
Chemotherapy-induced nausea and vomiting
1 trial -
Neugranin
Teva Pharma GmbH
Chemotherapy-induced Neutropenia
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.
1 trial -
Palliative Chemotherapy
Sun Yat-sen University
Colorectal Neoplasms Malignant
1 trial -
SHR8735-303
Lacuna Pharma Pty Ltd
Chemotherapy induced thrombocytopenia
1 trial -
Tibsovo 250 mg film-coated tablets
The George Institute
ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
1 trial -
Tislelizumab + SOX Chemotherapy
The First People's Hospital of Lianyungang
Gastric Cancer Stage III
1 trial -
UC-BCG-2501
Ningbo Cancer Hospital
Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy
1 trial -
UC-GIG-2408
Ningbo Cancer Hospital
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery
1 trial -
UC-IMM-2101
Ningbo Cancer Hospital
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Limited Stage Small Cell Lung Cancer
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
metronomic adjuvant chemotherapy with capecitabine
Chongqing Claruvis Pharmaceutical Co.,
Nasopharyngeal Cancinoma (NPC)
1 trial -
mitomycin C-based hyperthermic intraperitoneal chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
neoadjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Epithelial Ovarian Cancer
1 trial -
2022/3418 INDIGO
The George Institute
Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.
1 trial -
ADCETRIS 50 mg powder for concentrate for solution for infusion
Takeda
Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.